GlassScriptPhysician profile
Rhonda Rowan
NPI 1427568492
$9,987.79
in general payments reported to CMS, 2019-2025
22 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,019 · 2022: $2,115 · 2023: $2,594 · 2024: $2,338 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,853 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,852.91 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,676.29 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,177.55 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $976.42 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $814.30 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Corium, LLC | $622.21 | 2021-2024 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $597.95 | 2021-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $575.12 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $557.52 | 2021-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $525.45 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $513.35 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $421.20 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $369.90 | 2023-2024 | Auvelity |
| Lundbeck LLC | $350.04 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $280.38 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $216.96 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $79.40 | 2022-2024 | |
| Noven Therapeutics, LLC | $64.98 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $62.99 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $42.23 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $34.48 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.56 | 2021 | |
| Indivior INC. | $13.51 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Rowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.